SCHEMBL27734784

SCHEMBL27734784

O=C(O)N1CCC(NCc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.50
CHRNA7 P36544 1/20 0.49
TSHR P16473 4/20 0.46
RECQL P46063 2/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 3/20 0.46
EPHX2 P34913 1/20 0.44
KCNH2 Q12809 1/20 0.44
ROCK2 O75116 1/20 0.44
GRK2 P25098 1/20 0.44
S1PR1 P21453 1/20 0.43
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42
TUBB8 Q3ZCM7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL386914 0.85 GPR119 (0.72) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL4524278 0.84 TSHR (0.50) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL27769053 0.82 DRD4 (0.36) GPR119CHRNA7LMNAROCK2GRK2
SCHEMBL5133959 0.81 TSHR (0.68) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL1069801 0.80 GPR119 (0.74) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL2298624 0.78 NPC1 (0.56) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL5133503 0.78 KMT2A (0.61) TSHRSMN1; SMN2LMNAKCNH2ALDH1A1
SCHEMBL2292951 0.77 GPR119 (0.49) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL2300194 0.77 SMN1; SMN2 (0.50) GPR119CHRNA7TSHRRECQLSMN1; SMN2
SCHEMBL4513166 0.76 SMN1; SMN2 (0.73) TSHRSMN1; SMN2LMNAEPHX2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101332303-A Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level ARENA PHARM INC (US) 2008-12-31 CN disclosed